CJC / Ipamorelin

CJC-1295 + Ipamorelin

CJC-1295 and Ipamorelin are synthetic research peptides commonly studied together for their complementary activity within growth hormone–related signaling pathways. In preclinical research models, CJC-1295 has been shown to stimulate growth hormone–releasing hormone (GHRH) pathways, while Ipamorelin selectively interacts with ghrelin receptors involved in growth hormone secretion.

When combined in research settings, these compounds are studied for their potential effects on growth hormone pulsatility, protein synthesis signaling, metabolic regulation, and recovery-related pathways. Unlike earlier growth hormone secretagogues, Ipamorelin is noted in research literature for its receptor selectivity, making the combination a frequent subject of investigation in studies related to body composition, cellular repair mechanisms, and endocrine signaling dynamics.

For research use only. Not for human or veterinary use.